TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03133130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMT101
Description: BMT101 is administered to 6 subjects in each of 4 groups.
Study: NCT03557398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydeal-D vaginal pessaries
Description: One vaginal application of Hydeal-D vaginal pessaries every 3 days to a total of 12 consecutive weeks.
Study: NCT03133130

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered to 2 subjects in each of 4 groups.
Study: NCT00216476

Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole
Description: 10-30 mg oral once daily for 104 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Long Acting Injectable (LAI)
Description: 25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
Study: NCT02589210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EpiFix Mesh
Description: Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
Study: NCT03852758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor Exercise
Description: 2 outdoor exercise sessions per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor Exercise
Description: 2 outdoor exercise sessions per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indoor Exercise
Description: 2 indoor exercise sessions per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indoor Exercise
Description: 2 indoor exercise sessions per week
Study: NCT00468208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: A participant's abatacept dose depended on body weight and will remain the same throughout the study:~* 500 mg of abatacept for body weight less than 60 kg~* 750 mg of abatacept for body weight between 60 and 100 kg~* 1000 mg of abatacept for body weight greater than 100 kg~Abatacept is administered in a 30-minute intravenous infusion.
Study: NCT00129116

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib-MenCY-TT vaccine
Description: Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib-MenCY-TT vaccine
Description: Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib-MenCY-TT vaccine
Description: Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT vaccine
Description: Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate ®
Description: Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix penta ®
Description: Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix penta ®
Description: Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix penta ®
Description: Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix penta ®
Description: Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa ®
Description: Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
Study: NCT02182102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Study: NCT00631007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT131 besylate
Description: Once-daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT131 besylate
Description: Once-daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT131 besylate
Description: Once-daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT131 besylate
Description: Once-daily, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone HCl
Description: Once-daily, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily, oral
Study: NCT03703453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ER-REBOA catheter
Description: The ER-REBOA™ catheter is a device that has been gaining increased use in the setting of severe trauma for the purposes of stopping intra-abdominal hemorrhage. The catheter is advanced through a femoral artery sheath into the aorta, where a balloon at its tip is inflated, occluding all distal blood flow (and stopping any hemorrhage while the patient can be prepared for definitive operative intervention).
Study: NCT00731224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Study: NCT00973934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Theta

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thymatron System IV
Study: NCT04126343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive padsevonil in a pre-specified dosing sequence during the Treatment Period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive moxifloxacin once during the Treatment Period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive placebo in a pre-specified sequence during the Treatment Period to match padsevonil and maintain the blinding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive placebo in a pre-specified sequence during the Treatment Period to match padsevonil and maintain the blinding

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive placebo in a pre-specified sequence during the Treatment Period to match padsevonil and maintain the blinding
Study: NCT03885869

Intervention type: OTHER
Intervention: Ankle Joint Position Sensation Evaluation
Description: In this test, individuals are placed in the supine position with their eyes closed for prevent visual cues; measurements are performed with the plex of the goniometer, 1.5 cm below the lateral malleol, the fixed arm parallel to the long axis of the fibula and the movable arm parallel to the long axis of the 5th metatarsal. Desired target angles were defined as 10 ° dorsi flexion, 10 ° plantar flexion and 20 ° plantar flexion. Individuals are instructed to focus on the position of the ankle joints in space for 5 s by bringing the feet in neutral position to the target position by the researcher. This procedure is repeated 3 times and the patient is expected to learn this position. The target angle is then asked to repeat in the testing phase. The measurement is repeated 3 times for each target angle. As a result criterion; By recording the absolute value of the deviation amounts from the target angles; The averages of the deviations during the 3 repetitions are averaged.

Intervention type: OTHER
Intervention: Knee Joint Position Sensation Evaluation
Description: Bilateral knee joint position sensation will be evaluated in the literature with an analogue inclinometer(BASELINE®),which is a valid and reliable method for measuring joint position sensations.Measurements were planned to made in the sitting position,with the eyes of the individual closed and the joint to be evaluated bare,without any socks or shoes worn,fixing the inclinometer with a strap to the lower leg perpendicular to the knee flexion axis.In this measurement,the knees of the participants are passively shifted from the initial (90°flexion)position to the 30°flexion position,at this point 5 sec is waited and after they are told to keep this angle in mind,the starting position is returned.This procedure is repeated 3 times and the patient is expected to learn this position.After the individuals are rested for 5 s,they are asked to actively perform the target angle again.The same procedure was planned to be repeated 3 times for each angle at 45° and 60° knee flexion target angles.

Intervention type: OTHER
Intervention: The Evaluation of Plantar Sensation
Description: In the plantar sensory evaluation of the participants, Semmes-Wenstein Monofilament, which is frequently used in the literature and to be a reliable method in the diagnosis of neuropathy, was aimed to be tested by touching 7 regions on the foot base .~In this evaluation, the individual is in the supine position, the physiotherapist is at the foot end of the patient; monofilament should be applied 90⁰ to the surface.~The filament thickness which is the first feeling of the individual is recorded by being asked whether the individual is feeling. The 3 most commonly used monofilaments for patients with diabetic neuropathy are 4.17, 5.07 and 6.10 monofilaments. The highest monofilament value is the hardest and most difficult bending monofilament.
Study: NCT03832985

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Receive an adult-onset result
Description: Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Receive a pediatric-onset result
Description: Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Control - No Result
Description: Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have not received an adult-onset genomic result.
Study: NCT05460663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management and Resilience Training (SMART)
Description: The Stress Management and Resilience Training (SMART) program was developed by Dr. Amit Sood. SMART focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. The SMART program incorporates practices that focus on six individual factors that have been found to promote individual-level resilience: positive coping, positive affect, positive thinking, realism, behavioral control, and altruism. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) and in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management and Resilience Training (SMART)
Description: The Stress Management and Resilience Training (SMART) program was developed by Dr. Amit Sood. SMART focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. The SMART program incorporates practices that focus on six individual factors that have been found to promote individual-level resilience: positive coping, positive affect, positive thinking, realism, behavioral control, and altruism. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) and in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks.
Study: NCT02470104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breastmilk
Description: * A registered dietician will supervise milk provision.~* If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible with Prolacta supplementation if clinically indicated and recommended by the registered dietician.
Study: NCT04573374

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy
Description: Pulpotomy is the term for removal of the coronal pulp with the intent of maintaining the vitality of the remaining radicular pulp tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy
Description: Pulpotomy is the term for removal of the coronal pulp with the intent of maintaining the vitality of the remaining radicular pulp tissue.
Study: NCT01824836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies
Study: NCT03885869

Intervention type: OTHER
Intervention: The Evaluation of Balance
Description: In order to evaluate the static and dynamic balances of the participants, determination of open and closed postural oscillations and stability limits were planned with Prokin branded isokinetic balance system.

Intervention type: OTHER
Intervention: Evaluation of Dual Task Performance
Description: In order to evaluate double task performances, it is planned to evaluate 1 dynamic and 1 static 2 different performances, including Time Up and Go Test (TUG) and single leg standing time. For each performance; the single task, the motor second task and cognitive seconder tasks separately, and again for each application to be performed in such a way that two trials, the average time was planned to record. Motor and cognitive tasks for each test are planned as described below.~Motor Task (TUG): Carrying cup full of water on tray. Cognitive Task (TUG): Counting the days of the week backwards from the current day Motor Task (Single Leg Standing Time): Hand-Over ball transfer Cognitive Task (Single Leg Standing Time): Counting backward month names from the current month

Intervention type: OTHER
Intervention: General Evaluation Form
Description: A form, which is prepared by us, including demographic information and physical characteristics of the individuals.
Study: NCT06189911

Intervention type: PROCEDURE
Intervention: Open liver resection
Description: The definitions of liver resection and the type of hepatectomy were aligned with the anatomic classification of the Brisbane 2000 Terminology

Intervention type: PROCEDURE
Intervention: Open liver resection
Description: The definitions of liver resection and the type of hepatectomy were aligned with the anatomic classification of the Brisbane 2000 Terminology
Study: NCT00781092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Ultra
Description: Ophthalmic Solution, 1 gtt, three times daily to both eyes for 1 month post operative

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bausch and Lomb Sensitive Eyes
Description: Ophthalmic Solution, 1 gtt, three times a day in both eyes for 1 month after LASIK
Study: NCT02223286

Intervention type: DIAGNOSTIC_TEST
Intervention: Corus CAD
Description: Age/Sex/Gene Expression Score
Study: NCT01701973

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.

Intervention type: DRUG
Group type: OTHER
Intervention: Pegvisomant
Description: During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)

Intervention type: DRUG
Group type: OTHER
Intervention: L-NMMA
Description: During Aim 2, given during one of two study days (Group A subjects only)

Intervention type: DRUG
Group type: OTHER
Intervention: Exendin 9-39
Description: During Aim 2, given during one of two study days (Group C subjects only)
Study: NCT02076776

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Task Practice (RTP)
Description: This group will preform arm and hand therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary cycling + RTP
Description: This group will preform arm and hand therapy and cycle on a bike.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assisted cycling + RTP
Description: This group will preform arm and hand therapy and cycle on a bike.
Study: NCT01288391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0128-0000-2011
Description: Single dose of 100 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0128-0000-2011
Description: Single dose of 200 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
Study: NCT02067702

Intervention type: PROCEDURE
Intervention: Limb Cooling Assessment of ET
Description: The non-pharmacological treatment assessments of limb cooling will take place for the subjects which will include the upper limbs. Both clinical and physiological recordings will be measured for a difference in tremors at three different temperatures. 1)baseline assessment maintaining a normal body temperature (96-98°F). 2) at a temperature of 59°F and 3) at a temperature of 80°F for a period of 10 minutes. The clinical assessments will include the Tremor Rating Scale (TRS), Handwriting Assessment Battery (HAB) and the Functional Dexterity Test (FDT). In addition, the Bagnoli and Trigno EMG systems to record surface EMG signals from muscles and accelerometer readings.

Intervention type: PROCEDURE
Intervention: Limb Cooling Assessment of ET
Description: The non-pharmacological treatment assessments of limb cooling will take place for the subjects which will include the upper limbs. Both clinical and physiological recordings will be measured for a difference in tremors at three different temperatures. 1)baseline assessment maintaining a normal body temperature (96-98°F). 2) at a temperature of 59°F and 3) at a temperature of 80°F for a period of 10 minutes. The clinical assessments will include the Tremor Rating Scale (TRS), Handwriting Assessment Battery (HAB) and the Functional Dexterity Test (FDT). In addition, the Bagnoli and Trigno EMG systems to record surface EMG signals from muscles and accelerometer readings.
Study: NCT04747132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telegeriatric intervention
Description: Individualized, comprehensive and specialized counseling for older adults through the Internet
Study: NCT03405857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation program
Description: Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
Study: NCT02182102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study: NCT01823627

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Spirometry with reversibility test
Description: Spirometry with reversibility test and CATest questionaire. following will be measured FEV1 L/s FVC L/s FEV1/FVC ration
Study: NCT01465178

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 2000 IU cholecalciferol gelcaps by mouth daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT01570985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Triamcinolone 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and variable amount of saline of 4 ml solution on day 1, day 7, day 17 and day 31st.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Patients in group 2 will receive intraarticular Triamcinolone 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
Study: NCT03442335

Intervention type: DIAGNOSTIC_TEST
Intervention: Chromohysteroscopy
Description: Standard hysteroscopy followed by injection of a dye, in this case iodine.

Intervention type: DIAGNOSTIC_TEST
Intervention: Chromohysteroscopy
Description: Standard hysteroscopy followed by injection of a dye, in this case iodine.

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial biopsy (Pipelle)
Description: A narrow plastic tube (Pipelle) is passed through the cervix to aspirate a sample of endometrial tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: Endometrial biopsy (Pipelle)
Description: A narrow plastic tube (Pipelle) is passed through the cervix to aspirate a sample of endometrial tissue.